Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis

Article Abstract:

Boys who received prednisone to treat some complications of cystic fibrosis may be shorter than normal as adults. This was the conclusion of a study that followed 224 children with cystic fibrosis, 151 of whom had taken prednisone to treat lung disease but had stopped six or seven years prior to the study. By the time of the study, 68% were 18 years old or older. Catch-up growth began two years after the drug was stopped, but boys who had taken prednisone were still shorter than boys who had not. Girls were not affected by the drug as much as boys.

Causes of, Complications and side effects, Drug therapy, Growth disorders, Prednisone

---

Nutritional benefits of neonatal screening for cystic fibrosis

Article Abstract:

Testing newborn infants for cystic fibrosis may identify affected babies early and allow them to be treated to prevent any nutritional deficiencies. At one hospital, 650,341 newborn infants were tested between 1985 and 1994, which resulted in 56 infants being diagnosed with cystic fibrosis at an average age of 12 weeks. Their nutritional outcome was compared to 40 children who were diagnosed at an average age of 72 weeks. The early-diagnosis group was longer and heavier than the late-diagnosis group both at the time of diagnosis and 10 years later.

Evaluation, Food and nutrition, Infants (Newborn), Newborn infants, Medical screening, Health screening

---

Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis

Article Abstract:

A study is conducted to investigate the epidemiology of Pseudomonas aeruginosa infection and its impact on cystic fibrosis (CF) pulmonary morbidity. The conclusion suggests that early prevention and detection of nonmucoid and mucoid P aeruginosa are critical because of early acquisition and prevalence.

United States, Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Medical Research, Epilepsy & Muscle Disease R&D, Administration of Public Health Programs, Health Research Programs, Risk factors, Pseudomonas aeruginosa infections, Medicine, Experimental

Similar abstracts:

• Abstracts: Energy content of stools in normal healthy controls and patients with cystic fibrosis. Excessive faecal losses of vitamin A (retinol) in cystic fibrosis
• Abstracts: Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures
• Abstracts: Carrier screening for cystic fibrosis: implications for obstetric and gynecologic practice. Cystic fibrosis mutations in white and black Americans: an approach to identification of unknown mutations with implications for cystic fibrosis screening
• Abstracts: Microbiologic causes and neonatal outcomes associated with chorioamnion infection. The vaginal inflammatory milieu and the risk of the early premature preterm rupture of membranes
• Abstracts: A randomized, double-blind trial of prostaglandin E2 gel for cervical ripening and meta-analysis. part 2 Vaginal sonography and cervical incompetence

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.